RedHill Biopharma (RDHL) Gains from Investment Securities (2019 - 2022)
Historic Gains from Investment Securities for RedHill Biopharma (RDHL) over the last 4 years, with Q4 2022 value amounting to $823000.0.
- RedHill Biopharma's Gains from Investment Securities rose 110365.85% to $823000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $5.6 million, marking a year-over-year increase of 44377.43%. This contributed to the annual value of $270000.0 for FY2023, which is 9516.99% down from last year.
- As of Q4 2022, RedHill Biopharma's Gains from Investment Securities stood at $823000.0, which was up 110365.85% from $4.8 million recorded in Q1 2022.
- In the past 5 years, RedHill Biopharma's Gains from Investment Securities ranged from a high of $4.8 million in Q1 2022 and a low of -$82000.0 during Q4 2021
- Moreover, its 4-year median value for Gains from Investment Securities was $630000.0 (2020), whereas its average is $1.1 million.
- In the last 5 years, RedHill Biopharma's Gains from Investment Securities tumbled by 14270.83% in 2021 and then surged by 110365.85% in 2022.
- Quarter analysis of 4 years shows RedHill Biopharma's Gains from Investment Securities stood at $124000.0 in 2019, then skyrocketed by 54.84% to $192000.0 in 2020, then plummeted by 142.71% to -$82000.0 in 2021, then soared by 1103.66% to $823000.0 in 2022.
- Its last three reported values are $823000.0 in Q4 2022, $4.8 million for Q1 2022, and -$82000.0 during Q4 2021.